Serum Level of Tumor Marker Carbohydrate Antigen-CA125 in Heart Failure

Durak-Nalbantić, Azra; Resić, Nerma; Kulić, Mehmed; Pecar, Ehlimana; Zvizdić, Faris; Džubur, Alen; Dilić, Mirza; Gojak, Refet; Sokolović, Šekib; Hodžić, Enisa; Brdjanovic, Snezana

doi:10.5455/medarh.2013.67.241-244

Cited by 19 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Robust data showed that elevated BNP is highly predictive of AHF and all-cause mortality in ACS patients when compared with lower levels. Our results are also different from those of Azra Durak-Nalbantic1 et al, who found a signi cant although weak positive correlation of CA125 and BNP in CHF patients (r = 0.293, p < 0.05) [27]. Dursum Duman et al studied the relationship between the CA125 and BNP concentrations in patients with advanced HF: LnCA125 was signi cantly correlated with LnBNP (r = 0.78, p < 0.001), and CA125 levels were independently associated with BNP (β = 0.58, p < 0.001) [11].…”

Section: Discussioncontrasting

confidence: 99%

Prognostic Value of CA125 Serum Levels in Female Patients with Acute Coronary Syndrome

Luo¹,

Cheng²,

Zhang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: carbohydrate antigen 125 (CA125) is an increasingly promising biomarker of heart failure (HF), but its prognostic value in female patients with acute coronary syndrome (ACS) is unclear. We aimed to determine the short-term and mid-term prognostic value of CA125 serum levels in female ACS patients.Methods: A total of 131 consecutive female patients with ACS were retrospective enrolled. Their CA125 levels, B-type natriuretic peptide (BNP) levels and biochemical parameters were measured, and echocardiography was performed at admission. All-cause mortality during hospitalization and two-year follow-up was investigated for the prognosis.Results: The median value of CA125 serum level in the entire ACS patients was 13.85 U/mL. Patients in Killip Ⅲ had the highest values of CA125 level, followed by Killip Ⅱ and then Killip Ⅰ (p < 0.05). However, no statical difference was observed between Killip Ⅳ and Ⅰ-Ⅲ groups respectively (P > 0.05). The CA125 serum levels showed weak positive correlation with left ventricular end-diastolic diameter (LVEDD) (r = 0.3, P < 0.01) and a weak negative correlation with left ventricular ejection fraction (LVEF) (r = –0.23, p < 0.01). A receive operating characteristic (ROC) curve analysis showed that the AUC of CA125 in predicting acute heart failure (AHF) in ACS patients during hospitalization was 0.912, exhibiting higher sensitivity and specificity than BNP (0.846). The optimal cut-off value for CA125 in predicting AHF was 16.4 U/mL with a sensitivity of 0.916 and specificity of 0.893. The Kaplan-Meier survival analysis demonstrated that patients with high values of CA125 level had a poor overall survival than those with low values of CA125 level (log-rank, p < 0.001), whether during hospitalization or mid-term follow-up. Conclusion: Elevated CA125 level can be used to predict AHF in female ACS patients. Patients with elevated CA125 levels had higher mortality in short-term and mid-term than those with low CA125 levels.

show abstract

Section: Discussioncontrasting

confidence: 99%

Prognostic Value of CA125 Serum Levels in Female Patients with Acute Coronary Syndrome

Luo¹,

Cheng²,

Zhang³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…CA 125 could provide additional value in treatment guidance. Higher CA 125 levels in heart failure patients are predictive for more deaths and rehospitalizations (130) and a combination of BNP and CA 125 improves risk stratification at 6 months (131). Thus, the marker shows potential to influence medical therapy (132).…”

Section: "Out Of the Box" Biomarkers Tumor Markersmentioning

confidence: 99%

The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy

Topf

Mirna

Ohnewein

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Heart failure is a pathophysiological state, which is still associated with high morbidity and mortality despite established therapies. Diverse well-known biomarkers fail to assess the variety of individual pathophysiology in the context of heart failure.Methods: An analysis of prospective, multimarker-specific therapeutic approaches to heart failure based on studies in current literature was performed. A total of 159 screened publications in the field of biomarkers in heart failure were hand-selected and found to be eligible for this study by a team of experts.Results: Established biomarkers of the inflammatory axis, matrix remodeling, fibrosis and oxidative stress axis, as well as potential therapeutic interventions were investigated. Interaction with end organs, such as cardio-hepatic, cardio-renal and cardio-gastrointestinal interactions show the complexity of the syndrome and could be of further therapeutic value. MicroRNAs are involved in a wide variety of physiologic and pathophysiologic processes in heart failure and could be useful in diagnostic as well as therapeutic setting.Conclusion: Based on our analysis by a biomarker-driven approach in heart failure therapy, patients could be treated more specifically in long term with a consideration of different aspects of heart failure. New studies evaluating a multimarker – based therapeutic approach could lead in a decrease in the morbidity and mortality of heart failure patients.

show abstract

“…Although we did not collect specific information regarding the reasons for anticoagulant therapy, some of these patients likely had atrial fibrillation (AF). As AF is associated with heart failure, fluid retention and elevated CA 125 ( 33 ), patients with high probability of AF were excluded from the final analysis in our study. It is possible that increased CA 125 observed in some patients with kidney disease is associated more with fluid overload than impaired GFR.…”

Section: Discussionmentioning

confidence: 99%

Reference Limits for Chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and Carcinoembryonic Antigen in Patients with Chronic Kidney Disease

Mikkelsen

Åsberg

Hultström³

et al. 2017

Int J Biol Markers

View full text Add to dashboard Cite

BackgroundPatients with chronic kidney disease (CKD) may have increased plasma concentrations of some tumor markers even when no cancer is present. Previous studies have indicated that plasma concentrations of chromogranin A (CGA), cytokeratin 19 fragments (CYFRA 21-1), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in healthy individuals, and this can make interpretation of results more complicated. The aim of this study was to establish reference limits for these markers in patients with CKD not receiving dialysis and with no clinical evidence of cancer.MethodsWe measured plasma concentrations in samples from 131 patients with CKD due to various etiologies and studied the association of tumor marker concentrations with estimated glomerular filtration rate (GFR) and other patient characteristics.ResultsEstimated reference limits for plasma CA 125, CA 19-9 and CEA were approximately the same as for healthy populations. Serum concentrations of CGA and CYFRA 21-1 correlated strongly with estimated GFR, and GFR-dependent reference limits were estimated.ConclusionsGFR-dependent reference limits for CGA and CYFRA 21-1 are reported in order to support interpretation of these markers in patients with CKD.

show abstract

Serum Level of Tumor Marker Carbohydrate Antigen-CA125 in Heart Failure

Cited by 19 publications

References 12 publications

Prognostic Value of CA125 Serum Levels in Female Patients with Acute Coronary Syndrome

Prognostic Value of CA125 Serum Levels in Female Patients with Acute Coronary Syndrome

The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy

Reference Limits for Chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and Carcinoembryonic Antigen in Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About